![Penka Petrova](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Penka Petrova
Geen lopende functies
Profiel
Penka Petrova worked as a Director of Drug Development at Trillium Therapeutics, Inc. and as a Research Scientist at PNO Resources Ltd.
She then worked at Trillium Therapeutics ULC as the Chief Operating and Development Officer from 2015 to 2021.
Dr. Petrova holds a doctorate degree from Universität des Saarlandes.
Eerdere bekende functies van Penka Petrova
Bedrijven | Functie | Einde |
---|---|---|
TRILLIUM THERAPEUTICS | Operationeel Directeur | 17-11-2021 |
PNO Resources Ltd.
![]() PNO Resources Ltd. Other Metals/MineralsNon-Energy Minerals PNO Resources Ltd. engages in the acquisition and exploration of natural resource properties. The company was founded on February 22, 1983 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Corporate Officer/Principal | - |
Opleiding van Penka Petrova
Universität des Saarlandes | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
PNO Resources Ltd.
![]() PNO Resources Ltd. Other Metals/MineralsNon-Energy Minerals PNO Resources Ltd. engages in the acquisition and exploration of natural resource properties. The company was founded on February 22, 1983 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |
Trillium Therapeutics ULC
![]() Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |